Baxter/Hyland Gammagard S.D.
Solvent detergent treated immune globulin I.V. product approved for the treatment of life-threatening immune disorders such as lymphocytic leukemia and acute idiopathic thrombocytopenic purpura, Baxter reports. The company voluntarily withdrew Gammagard in February ("The Pink Sheet" March 7, T&G-2). In addition to providing greater safety against viral contamination, Gammagard S.D. becomes available in a 10% concentration that allows physicians to administer the product in half the time
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth